MA39172B1 - Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines - Google Patents

Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines

Info

Publication number
MA39172B1
MA39172B1 MA39172A MA39172A MA39172B1 MA 39172 B1 MA39172 B1 MA 39172B1 MA 39172 A MA39172 A MA 39172A MA 39172 A MA39172 A MA 39172A MA 39172 B1 MA39172 B1 MA 39172B1
Authority
MA
Morocco
Prior art keywords
inhibitors
bromodomaine
bicyclic derivatives
heterocyclic bicyclic
heterocyclic
Prior art date
Application number
MA39172A
Other languages
English (en)
Other versions
MA39172A1 (fr
Inventor
Susanta Samajdar
Chandrasekhar Abbineni
Sanjita Sasmal
Subramanya Hosahalli
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MA39172A1 publication Critical patent/MA39172A1/fr
Publication of MA39172B1 publication Critical patent/MA39172B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La présente invention concerne des dérivés bicycliques hétérocycliques de formule (i), qui peuvent être thérapeutiquement utiles, plus particulièrement comme inhibiteurs de bromodomaines ; (i), dans laquelle r
MA39172A 2014-01-09 2015-01-06 Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines MA39172B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN125CH2014 2014-01-09
PCT/IB2015/050090 WO2015104653A1 (fr) 2014-01-09 2015-01-06 Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines

Publications (2)

Publication Number Publication Date
MA39172A1 MA39172A1 (fr) 2018-04-30
MA39172B1 true MA39172B1 (fr) 2018-10-31

Family

ID=52462967

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39172A MA39172B1 (fr) 2014-01-09 2015-01-06 Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines

Country Status (30)

Country Link
US (2) US10077259B2 (fr)
EP (1) EP3092227B1 (fr)
JP (1) JP6480944B2 (fr)
KR (1) KR102394518B1 (fr)
CN (1) CN106061966B (fr)
AU (1) AU2015205339B2 (fr)
BR (1) BR112016015311B1 (fr)
CA (1) CA2934788C (fr)
CL (1) CL2016001737A1 (fr)
CY (1) CY1122046T1 (fr)
DK (1) DK3092227T3 (fr)
EA (1) EA029224B1 (fr)
ES (1) ES2687497T3 (fr)
HR (1) HRP20181650T1 (fr)
HU (1) HUE041546T2 (fr)
IL (1) IL246140B (fr)
LT (1) LT3092227T (fr)
MA (1) MA39172B1 (fr)
MX (1) MX2016009052A (fr)
MY (1) MY190835A (fr)
PE (1) PE20161021A1 (fr)
PH (1) PH12016501355B1 (fr)
PL (1) PL3092227T3 (fr)
PT (1) PT3092227T (fr)
RS (1) RS57586B1 (fr)
SA (1) SA516371448B1 (fr)
SG (1) SG11201604916YA (fr)
SI (1) SI3092227T1 (fr)
UA (1) UA117165C2 (fr)
WO (1) WO2015104653A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3581576B1 (fr) 2013-03-15 2022-01-26 Incyte Holdings Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de protéine bet utiles pour le traitement d'une maladie proliférante en combinaison avec un inhibiteur de kinase janus
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
CN106414442B (zh) 2014-04-23 2019-03-15 因赛特公司 作为BET蛋白抑制剂的1H-吡咯并[2,3-c]吡啶-7(6H)-酮和吡唑并[3,4-c]吡啶-7(6H)-酮
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US20180312496A1 (en) * 2015-07-02 2018-11-01 Orion Corporation Bicyclic heterocycle derivatives as bromodomain inhibitors
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
US10501438B2 (en) 2015-08-11 2019-12-10 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
ES2904258T3 (es) 2015-08-12 2022-04-04 Neomed Inst Bencimidazoles sustituidos, su preparación y su uso como productos farmacéuticos
WO2017066876A1 (fr) 2015-10-21 2017-04-27 Neomed Institute Imidazopyridines substituées, leur préparation et leur utilisation comme médicaments
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
CN105198871A (zh) * 2015-11-06 2015-12-30 中国药科大学 一类喹喔啉酮类化合物及其制备方法和用途
WO2017127930A1 (fr) 2016-01-28 2017-08-03 Neomed Institute [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments
WO2017184462A1 (fr) * 2016-04-18 2017-10-26 Celgene Quanticel Research, Inc. Composés thérapeutiques
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
FI3472157T3 (fi) 2016-06-20 2023-06-01 Incyte Corp Bet-inhibiittorin kiteisiä kiinteitä muotoja
CN110337436A (zh) 2016-12-22 2019-10-15 拜耳作物科学股份公司 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途
WO2018114663A1 (fr) 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Azolylpyrrolones et azolylhydantoïnes substituées et leurs sels et leur utilisation comme agents herbicides
CN108570038B (zh) * 2017-03-08 2021-09-28 中国科学院上海药物研究所 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途
TWI788343B (zh) 2017-04-18 2023-01-01 美商塞爾基因定量細胞研究公司 治療用化合物
CN110092782B (zh) * 2018-01-30 2022-10-21 中国科学院广州生物医药与健康研究院 一种苯并六元氮杂环化合物及其制备方法和应用
CN110960528A (zh) * 2018-09-30 2020-04-07 四川大学 Ar和bet双重抑制剂及其用途
US11192900B2 (en) 2018-10-30 2021-12-07 Nuvation Bio Inc. Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
CA3132934A1 (fr) 2019-04-11 2020-10-15 Eila Luukkonen Forme cristalline d'un inhibiteur bet et sa fabrication
CA3145827A1 (fr) 2019-07-02 2021-01-07 Nuvation Bio Inc. Composes heterocycliques utilises en tant qu'inhibiteurs de bet
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR102600176B1 (ko) * 2021-10-18 2023-11-10 주식회사 사피엔스바이오 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10259176A (ja) * 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
JP3906471B1 (ja) * 2004-09-28 2007-04-18 大塚製薬株式会社 カルボスチリル化合物
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
JP5191155B2 (ja) * 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
TW200918058A (en) * 2007-08-31 2009-05-01 Organon Nv TSH receptor antagonizing tetrahydroquinoline compounds
WO2009037343A1 (fr) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibiteurs de l'interaction entre mdm2 et p53
EP2239264A4 (fr) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp Agent antitumoral
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (fr) * 2011-08-22 2013-02-28 Pfizer Inc. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine
US9321750B2 (en) * 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
US9447069B2 (en) * 2012-04-30 2016-09-20 Innov17 Llc ROR modulators and their uses
CN105407894A (zh) * 2013-03-14 2016-03-16 康威基内有限公司 用于抑制含布罗莫结构域的蛋白质的方法和组合物
JP6453845B2 (ja) * 2013-03-27 2019-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｒｄ４阻害薬としてのジヒドロキナゾリノン類似体

Also Published As

Publication number Publication date
PL3092227T3 (pl) 2018-12-31
MX2016009052A (es) 2016-09-09
US20180339982A1 (en) 2018-11-29
HUE041546T2 (hu) 2019-05-28
EP3092227A1 (fr) 2016-11-16
WO2015104653A1 (fr) 2015-07-16
US10590118B2 (en) 2020-03-17
JP2017502057A (ja) 2017-01-19
KR20160106164A (ko) 2016-09-09
NZ721993A (en) 2021-05-28
EA029224B1 (ru) 2018-02-28
AU2015205339A1 (en) 2016-07-07
SI3092227T1 (sl) 2018-10-30
CY1122046T1 (el) 2020-07-31
LT3092227T (lt) 2018-08-10
JP6480944B2 (ja) 2019-03-13
CN106061966B (zh) 2018-12-07
SG11201604916YA (en) 2016-07-28
US10077259B2 (en) 2018-09-18
DK3092227T3 (en) 2018-09-03
PE20161021A1 (es) 2016-11-09
RS57586B1 (sr) 2018-11-30
MY190835A (en) 2022-05-12
EP3092227B1 (fr) 2018-07-11
ES2687497T3 (es) 2018-10-25
PH12016501355A1 (en) 2017-02-06
IL246140B (en) 2019-09-26
CL2016001737A1 (es) 2017-02-03
MA39172A1 (fr) 2018-04-30
CA2934788C (fr) 2021-12-07
BR112016015311B1 (pt) 2023-01-24
UA117165C2 (uk) 2018-06-25
BR112016015311A2 (fr) 2017-08-08
PT3092227T (pt) 2018-10-24
HRP20181650T1 (hr) 2018-12-14
IL246140A0 (en) 2016-08-02
US20160368906A1 (en) 2016-12-22
CA2934788A1 (fr) 2015-07-16
EA201691404A1 (ru) 2016-10-31
SA516371448B1 (ar) 2018-10-15
PH12016501355B1 (en) 2017-02-06
CN106061966A (zh) 2016-10-26
KR102394518B1 (ko) 2022-05-06
AU2015205339B2 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
EA201892147A1 (ru) Бициклические соединения
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201590534A1 (ru) Новые бициклические производные
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
EA201300730A1 (ru) Производные индазолилтриазола
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
EA201490846A1 (ru) Новые производные арилхинолина
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201270253A1 (ru) Производные n1-ацил-5-фторпиримидинона
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2